Efficacy of curcumin, and a saffron/curcumin combination for the treatment of major depression: A randomised, double-blind, placebo-controlled study

Journal of Affective Disorders

Volumn 207, Issue , 2017, Pages 188-196

  Lopresti, Adrian L ^a   Drummond, Peter D ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

Antidepressant; Clinical Trial; Curcumin; Depression; Saffron; Turmeric

Indexed keywords

CROCUS SATIVUS EXTRACT; CURCUMIN; PLACEBO; ANTIDEPRESSANT AGENT; PLANT EXTRACT;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; ATYPICAL DEPRESSION; CONSTIPATION; CONTROLLED STUDY; DEPRESSIVE SYMPTOMATOLOGY SELF RATED VERSION; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY EYE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HOT FLUSH; HUMAN; INCREASED APPETITE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIGRAINE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; STATE TRAIT ANXIETY INVENTORY; STOMACH PAIN; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE; VIVID DREAM; ADOLESCENT; COMBINATION DRUG THERAPY; CROCUS; DOSE RESPONSE; DRUG ADMINISTRATION; MIDDLE AGED; PHYTOTHERAPY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CROCUS; CURCUMIN; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84991262786     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2016.09.047     Document Type: Article

References (47)

1. Aggarwal, B.B., Gupta, S.C., Sung, B., Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br. J. Pharmacol. 169 (2013), 1672–1692.
2. Akhondzadeh Basti, A., Moshiri, E., Noorbala, A.A., Jamshidi, A.H., Abbasi, S.H., Akhondzadeh, S., Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: a pilot double-blind randomized trial. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 31 (2007), 439–442.
3. Akhondzadeh, S., Fallah-Pour, H., Afkham, K., Jamshidi, A.H., Khalighi-Cigaroudi, F., Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement. Altern. Med., 4, 2004, 12.
4. Al-Karawi, D., Al Mamoori, D.A., Tayyar, Y., The role of curcumin administration in patients with major depressive disorder: mini meta-analysis of clinical trials. Phytother. Res. 30 (2015), 175–183.
5. Antony, B., Merina, B., Iyer, S., Judy, N., Lennertz, K., Joyal, S., A pilot cross-over study to evaluate human oral bioavailability of BCM-95 CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Indian J. Pharm. Sci., 2008, 445–450.
6. Bauer, M., Glenn, T., Conell, J., Rasgon, N., Marsh, W., Sagduyu, K., Munoz, R., Lewitzka, U., Bauer, R., Pilhatsch, M., Monteith, S., Whybrow, P.C., Common use of dietary supplements for bipolar disorder: a naturalistic, self-reported study. Int. J. Bipolar Disord., 3, 2015, 29.
7. Belcaro, G., Cesarone, M.R., Dugall, M., Pellegrini, L., Ledda, A., Grossi, M.G., Togni, S., Appendino, G., Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern. Med. Rev. 15 (2010), 337–344.
8. Benammi, H., El Hiba, O., Romane, A., Gamrani, H., A blunted anxiolytic like effect of curcumin against acute lead induced anxiety in rat: involvement of serotonin. Acta Histochem. 116 (2014), 920–925.
9. Bergman, J., Miodownik, C., Bersudsky, Y., Sokolik, S., Lerner, P.P., Kreinin, A., Polakiewicz, J., Lerner, V., Curcumin as an add-on to antidepressive treatment: a randomized, double-blind, placebo-controlled, pilot clinical study. Clin. Neuropharmacol. 36 (2013), 73–77.
10. Corruble, E., Legrand, J.M., Duret, C., Charles, G., Guelfi, J.D., IDS-C and IDS-sr: psychometric properties in depressed in-patients. J. Affect. Disord. 56 (1999), 95–101.
11. Esmaily, H., Sahebkar, A., Iranshahi, M., Ganjali, S., Mohammadi, A., Ferns, G., Ghayour-Mobarhan, M., An investigation of the effects of curcumin on anxiety and depression in obese individuals: a randomized controlled trial. Chin. J. Integr. Med. 21 (2015), 332–338.
12. Gelenberg, A.J., The prevalence and impact of depression. J. Clin. Psychiatry, 71, 2010, e06.
13. Goethe, J.W., Woolley, S.B., Cardoni, A.A., Woznicki, B.A., Piez, D.A., Selective serotonin reuptake inhibitor discontinuation: side effects and other factors that influence medication adherence. J. Clin. Psychopharmacol. 27 (2007), 451–458.
14. Haider, S., Naqvi, F., Batool, Z., Tabassum, S., Sadir, S., Liaquat, L., Naqvi, F., Zuberi, N.A., Shakeel, H., Perveen, T., Pretreatment with curcumin attenuates anxiety while strengthens memory performance after one short stress experience in male rats. Brain Res. Bull. 115 (2015), 1–8.
15. Hausenblas, H.A., Saha, D., Dubyak, P.J., Anton, S.D., Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of randomized clinical trials. J. Integr. Med. 11 (2013), 377–383.
16. Hickman, R.J., Khambaty, T., Stewart, J.C., C-reactive protein is elevated in atypical but not nonatypical depression: data from the National Health and Nutrition Examination Survey (NHANES) 1999–2004. J. Behav. Med., 2013.
17. Kennedy, B.L., Schwab, J.J., Morris, R.L., Beldia, G., Assessment of state and trait anxiety in subjects with anxiety and depressive disorders. Psychiatr. Q. 72 (2001), 263–276.
18. Kozela, M., Bobak, M., Besala, A., Micek, A., Kubinova, R., Malyutina, S., Denisova, D., Richards, M., Pikhart, H., Peasey, A., Marmot, M., Pajak, A., The association of depressive symptoms with cardiovascular and all-cause mortality in Central and Eastern Europe: prospective results of the HAPIEE study. Eur. J. Prev. Cardiol., 2016.
19. Lamers, F., Vogelzangs, N., Merikangas, K.R., de Jonge, P., Beekman, A.T., Penninx, B.W., Evidence for a differential role of HPA-axis function, inflammation and metabolic syndrome in melancholic versus atypical depression. Mol. Psychiatry 18:6 (2013), 692–699.
20. Laursen, T.M., Musliner, K.L., Benros, M.E., Vestergaard, M., Munk-Olsen, T., Mortality and life expectancy in persons with severe unipolar depression. J. Affect. Disord. 193 (2016), 203–207.
21. Lopresti, A.L., Drummond, P.D., Saffron (Crocus sativus) for depression: a systematic review of clinical studies and examination of underlying antidepressant mechanisms of action. Hum. Psychopharmacol. 29 (2014), 517–527.
22. Lopresti, A.L., Hood, S.D., Drummond, P.D., Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J. Psychopharmacol. 26 (2012), 1512–1524.
23. Lopresti, A.L., Maes, M., Hood, S.D., Maker, G.L., Drummond, P.D., Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J. Affect. Disord. 167 (2014), 368–375.
24. Mazidi, M., Shemshian, M., Mousavi, S.H., Norouzy, A., Kermani, T., Moghiman, T., Sadeghi, A., Mokhber, N., Ghayour-Mobarhan, M., Ferns, G.A., A double-blind, randomized and placebo-controlled trial of Saffron (Crocus sativus L.) in the treatment of anxiety and depression. J. Complement. Integr. Med. 13 (2016), 195–199.
25. Metzger, R.L., A reliability and validity study of the state-trait anxiety inventory. J. Clin. Psychol. 32 (1976), 276–278.
26. Noorbala, A.A., Akhondzadeh, S., Tahmacebi-Pour, N., Jamshidi, A.H., Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J. Ethnopharmacol. 97 (2005), 281–284.
27. Okun, A., Stein, R.E., Bauman, L.J., Silver, E.J., Content validity of the Psychiatric Symptom Index, CES-depression scale, and State-Trait Anxiety Inventory from the perspective of DSM-IV. Psychol. Rep. 79 (1996), 1059–1069.
28. Panahi, Y., Badeli, R., Karami, G.R., Sahebkar, A., Investigation of the efficacy of adjunctive therapy with bioavailability-boosted curcuminoids in major depressive disorder. Phytother. Res. 29 (2015), 17–21.
29. Richards, D., Prevalence and clinical course of depression: a review. Clin. Psychol. Rev. 31 (2011), 1117–1125.
30. Rush, A.J., Carmody, T., Reimitz, P.E., The Inventory of Depressive Symptomatology (IDS): Clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int. J. Methods Psychiatr. Res. 9 (2000), 45–59.
31. Rush, A.J., Giles, D.E., Schlesser, M.A., Fulton, C.L., Weissenburger, J., Burns, C., The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res. 18 (1986), 65–87.
32. Rush, A.J., Gullion, C.M., Basco, M.R., Jarrett, R.B., Trivedi, M.H., The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol. Med. 26 (1996), 477–486.
33. Sahebkar, A., Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother. Res.: PTR 28 (2014), 633–642.
34. Sanmukhani, J., Satodia, V., Trivedi, J., Patel, T., Tiwari, D., Panchal, B., Goel, A., Tripathi, C.B., Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother. Res.: PTR 28 (2014), 579–585.
35. Shahmansouri, N., Farokhnia, M., Abbasi, S.H., Kassaian, S.E., Noorbala Tafti, A.A., Gougol, A., Yekehtaz, H., Forghani, S., Mahmoodian, M., Saroukhani, S., Arjmandi-Beglar, A., Akhondzadeh, S., A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J. Affect. Disord. 155 (2014), 216–222.
36. Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E., Hergueta, T., Baker, R., Dunbar, G.C., The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 59:Suppl 20 (1998), 22–33 (quiz 34–57).
37. Singh, T., Williams, K., Atypical depression. Psychiatry 3 (2006), 33–39.
38. Sinyor, M., Schaffer, A., Levitt, A., The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can. J. Psychiatry 55 (2010), 126–135.
39. Spielberger, C.D., State-Trait Anxiety Inventory. A Comprehensive Bibliography, 1983, Consulting Psychologists Press, Palo Alto, CA.
40. Tabachnick, B.G., Fidell, L.S., Using Multivariate Statistics. 5th ed., 2007, Allyn, Boston.
41. Talaei, A., Hassanpour Moghadam, M., Sajadi Tabassi, S.A., Mohajeri, S.A., Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. J. Affect. Disord. 174 (2015), 51–56.
42. Trivedi, M.H., Rush, A.J., Ibrahim, H.M., Carmody, T.J., Biggs, M.M., Suppes, T., Crismon, M.L., Shores-Wilson, K., Toprac, M.G., Dennehy, E.B., Witte, B., Kashner, T.M., The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol. Med. 34 (2004), 73–82.
43. Warden, D., Rush, A.J., Trivedi, M.H., Fava, M., Wisniewski, S.R., The STAR*D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 9 (2007), 449–459.
44. WHO, 2008. The Global Burden of Disease: 2004 Update. World Health Organization, Available at: (www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html) (accessed 10.04.12).
45. Wu, P., Fuller, C., Liu, X., Lee, H.C., Fan, B., Hoven, C.W., Mandell, D., Wade, C., Kronenberg, F., Use of complementary and alternative medicine among women with depression: results of a national survey. Psychiatr. Serv. 58 (2007), 349–356.
46. Yu, J.J., Pei, L.B., Zhang, Y., Wen, Z.Y., Yang, J.L., Chronic supplementation of curcumin enhances the efficacy of antidepressants in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J. Clin. Psychopharmacol. 35 (2015), 406–410.
47. Zhou, H., Beevers, C.S., Huang, S., The targets of curcumin. Curr. Drug Targets 12 (2011), 332–347.